Metraipolis › archive › dc_47cbaefe1582
Additive effects of fecal microbiota transplantation and infliximab on gut microbiome and metabolome in refractory inflammatory bowel disease patients — Europe PMC PMID:41870087
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41870087
- DOI
- 10.1128/msystems.00774-25
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-04T02:51:27.108Z
- SHA-256 of the archived text
e786f72dbd28212551afc71f2b325ad214a49173519e2f466d7ff310f522d7c8- Stable URL of this page
https://metraipolis.com/documento/dc_47cbaefe1582
How to cite
Additive effects of fecal microbiota transplantation and infliximab on gut microbiome and metabolome in refractory inflammatory bowel disease patients — Europe PMC PMID:41870087 — Europe PMC (en), https://europepmc.org/article/MED/41870087 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_47cbaefe1582 (Metraipolis archive dc_47cbaefe1582, sha256 e786f72dbd28212551afc71f2b325ad214a49173519e2f466d7ff310f522d7c8)
BibTeX
@misc{dc47cbaefe1582,
title = {Additive effects of fecal microbiota transplantation and infliximab on gut microbiome and metabolome in refractory inflammatory bowel disease patients — Europe PMC PMID:41870087},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41870087},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_47cbaefe1582; sha256 e786f72dbd28212551afc71f2b325ad214a49173519e2f466d7ff310f522d7c8},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41870087. Agents can read the archived copy with the MCP tool read_document.